Cancer Immunology

Cancer Immunology refers to the relationship between immune function and cancer. The immunological mechanisms involved in cancer growth are highly complex and provide numerous potential points for intervention with small molecules, including extracellular enzymes, receptors and intracellular signal transduction pathways.

Cancer Immunology Products Targets

Products for Cancer Immunology - Page 15

Cat.No. Product Name Information/Activity
BCC1319 A 83-01 A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12, 45 and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
BCC1508 D4476 D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(CK1) with an IC50 value of 0.3 μM in vitro.
BCC3666 GW788388 GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
BCC5085 LY364947 LY-364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II.
BCC1887 RepSox RepSox is a potent and selective of the TGFβR-1/ALK5 inhibitor which inhibits ALK5 autophosphorylation with IC50 of 4 nM.
BCC3658 SB 431542 SB-431542 is a potent and selective inhibitor of ALK5/TGF-β type I Receptor with an IC50 value of 94 nM.
BCC5087 SB505124 SB-505124 is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
BCC2531 SB525334 SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
BCC1938 SD-208 SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
BCC2492 Imiquimod Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.